UNITED STATES OF AMERICA 

DEPARTMENT OF TRANSPORTATION 

FEDERAL AVIATION ADMINISTRATION 

WASHINGTON, DC 20591

In the matter of the petition of 

Caribbean Sun Airlines, Inc d/b/a World Atlantic Airlines 

Regulatory Docket No. FAA-2013-0034 for an exemption from 121.803 (c) (3) and Part 121, 

Appendix A, paragraph (2) of Title 14, Code of Federal Regulations

PARTIAL GRANT OF EXEMPTION

World Atlantic Airlines, with a mailing address of P.O. Box 660479, Miami Springs FL, 33266 and a physical address of 

5600 NW 36th Street, Miami, FL 33166 is petitioning the Federal Aviation Administration (FAA) for an exemption 

from CFR 121.803(c)(3) and Appendix A of CFR 121, Title 14, Code of Federal Regulations. The proposed exemption, 

if granted, would provide relief from the requirement to include Atropine in an Emergency Medical Kit (EMK). This 

petition is due to a nationwide manufacturing supply shortage that leaves affected certificate holders without an alternate 

means to comply with the requirements of Appendix A.

World Atlantic Airlines requires relief from the following regulations:

Section 121.803(c))(3) prescribes, in pertinent part, that passenger-carrying airplanes operating under part 121 rules for 

which a flight attendant is required must have approved emergency medical kits that meet the specifications and 

requirements of Part 121, Appendix A. Part 121, Appendix A, "Emergency Medical Kits" specifies, in pertinent part, that 

an EMK must include two single dose ampules of Atropine 0.5, Sec injectable or equivalent.

World Atlantic Airlines supports its request with the following information: Atropine, a medication required to be 

carried in EMKs, is not available due to a manufacturing shortfall and an increase in demand. Our major EMK supplier 

has indicated that its Atropine supply has been depleted. As such, we will not be able to meet the atropine requirement.

World Atlantic Airlines has attached a letter from our emergency equipment provider, Aerospace Accessory Service, 

Inc., concerning the unavailability of Atropine as evidence of the Atropine shortage. Further to this, we are aware of the

four pharmaceutical companies that manufacture Atropine and that one manufacturer has decided to stop producing 

Atropine and another has decided to indefinitely postpone Atropine production. This lack of production has resulted in

two remaining manufacturers rationing remaining supplies to first-line responders such as hospitals and paramedic units. 

Finally, World Atlantic Airlines requests that they be able to exercise the privileges of the exemption outside the United 

States. The International Civil Aviation Organization (ICAO) standards require aircraft authorized to carry more than 

100 passengers to be equipped with "accessible and adequate medical supplies," but recommends that injectable 

Atropine be available as part of a medical kit for use by medical doctors or other qualified persons on certain aircraft. 

Accordingly, we believe that the absence of Atropine in an EMK on an aircraft operating outside the United States 

would not violate ICAO requirements.

For the above stated reasons, World Atlantic Airlines is requesting an exemption from 121.803 (c) (3) and Part 121, 

Appendix A, paragraph (2) of Title 14, Code of Federal Regulations.

Sincerely,

John Rupert

V.P. / Director of Operations

Caribbean Sun Airlines, Inc.

d/b/a World Atlantic Airlines

(305) 722-6118